Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
06/01/2022 - 07:00 AM
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 8:00 a.m. ET .
A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycle’s website at www.bicycletherapeutics.com . An archived replay of the webcast will be available for 90 days following the fireside chat date.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles , for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK , with many key functions and members of its leadership team located in Lexington, Massachusetts . For more information, visit bicycletherapeutics.com.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220601005221/en/
Investors:
David Borah , CFA
david.borah@bicycletx.com
Media:
Argot Partners
Sarah Sutton
bicycle@argotpartners.com
Source: Bicycle Therapeutics
BCYC Rankings
#4392 Ranked by Stock Gains
BCYC Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Biotechnology, Pharmaceuticals: Major, Health Technology
Country
United Kingdom
City
Cambridge
About BCYC
bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
